EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
7129232 |
May 15, 2028 |
COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
7129232 |
May 15, 2028 |
COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
7129232 |
May 15, 2028 |
METHODS FOR TREATING BACTERIAL INFECTIONS |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
7129232 |
May 15, 2028 |
METHODS OF TREATING BACTERIAL ILLNESSES |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
10028963 |
Sept. 7, 2032 |
TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
10028963 |
Sept. 7, 2032 |
TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
9724353 |
Sept. 7, 2032 |
TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
9724353 |
Sept. 7, 2032 |
TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
8685957 |
Sept. 27, 2032 |
METHODS OF TREATING BACTERIAL ILLNESSES |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
10420841 |
March 14, 2034 |
COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
10420841 |
March 14, 2034 |
COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
10420841 |
March 14, 2034 |
TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
10420841 |
March 14, 2034 |
TREATMENT OF COMPLICATED URINARY TRACT INFECTION |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
11278622 |
March 14, 2034 |
TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
11278622 |
March 14, 2034 |
TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
8968753 |
March 14, 2034 |
COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
8968753 |
March 14, 2034 |
COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
8968753 |
March 14, 2034 |
TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
8968753 |
March 14, 2034 |
TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
10376496 |
Sept. 9, 2034 |
TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
10376496 |
Sept. 9, 2034 |
TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
10933053 |
Sept. 9, 2034 |
TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL |
ZERBAXA |
CUBIST PHARMS LLC |
N206829 |
Dec. 19, 2014 |
RX |
POWDER |
INTRAVENOUS |
10933053 |
Sept. 9, 2034 |
TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |